McCune C Anne, Ravine David, Worwood Mark, Jackson Helen A, Evans H Martyn, Hutton David
Department of Haematology, University of Wales College of Medicine, Heath Park, CF14 4XN, Cardiff, UK.
Lancet. 2003 Dec 6;362(9399):1897-8. doi: 10.1016/S0140-6736(03)14963-X.
Screening programmes for haemochromatosis that include follow-up identification of relatives are claimed to be cost effective. We assessed uptake of screening by first-degree relatives of two groups of index cases: people homozygous for the C282Y mutation ascertained by genetic screening of blood donors; and patients presenting clinically with haemochro matosis. Only 40 (24%) of 165 relatives of blood donors had been tested. By contrast, testing uptake in 121 relatives of patients diagnosed clinically was more than double that (53%), despite unstructured provision of genetic information. A substantial number of untested relatives had undiagnosed iron overload. Overall efficacy of population screening for haemochromatosis is undermined by these observations.
声称包括对亲属进行后续鉴定的血色素沉着症筛查计划具有成本效益。我们评估了两组索引病例的一级亲属的筛查接受情况:通过对献血者进行基因筛查确定为C282Y突变纯合子的人群;以及临床上表现出血色素沉着症的患者。在165名献血者亲属中,只有40人(24%)接受了检测。相比之下,在121名临床诊断患者的亲属中,检测接受率超过两倍(53%),尽管遗传信息的提供缺乏系统性。大量未接受检测的亲属存在未被诊断出的铁过载。这些观察结果削弱了血色素沉着症人群筛查的总体效果。